NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study

@article{Berzigotti2010NCX1000AN,
  title={NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study},
  author={A Berzigotti and Pau Bellot and Andrea de Gottardi and Juan Carlos Garc{\'i}a-Pag{\'a}n and Caroline Gagnon and Jean Sp{\'e}nard and J Bosch},
  journal={The American Journal of Gastroenterology},
  year={2010},
  volume={105},
  pages={1094-1101}
}
OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of ursodeoxycholic acid (UDCA), which showed selective vasodilatory effect on intrahepatic circulation in animal models of cirrhosis. This study was aimed at testing the efficacy and tolerability of this compound in patients with cirrhosis and portal hypertension.METHODS:This was a single-center, phase-2a, randomized (4:1), double-blind, parallel-group, dose-escalating… CONTINUE READING